시장보고서

상품코드

1781985

모노클로널 항체 시장 : 공급원 유형별, 생산 유형별, 적응증별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Monoclonal Antibody Market, By Source Type, By Production Types, By Indication, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 07월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 301 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

모노클로널 항체 시장 규모는 2024년에 2억 5,028만 달러에 달하며, 2025-2032년에 CAGR 11.92%로 확대

모노클로널 항체 시장 - 시장 역학

만성질환 증가와 생명공학의 발전으로 모노클로널 항체 시장 성장 가속화 전망

암, 자가면역질환 등 만성질환 증가로 모노클로널 항체치료에 대한 관심이 높아지고 있습니다. 생명공학의 비약적인 발전으로 질병 메커니즘을 보다 정확하게 표적화하여 치료 효과와 환자 예후를 개선할 수 있게 되었습니다. 예를 들어 미국 식품의약국(FDA)은 지난 5년 동안에만 20개 이상의 모노클로널 항체 기반 의약품을 승인했으며, 이는 이러한 치료법에 대한 신뢰가 높아졌음을 반영합니다. 또한 미국 국립보건원(NIH)과 같은 기관의 구상은 생물제제 연구 자금을 지원하고, 혁신적인 임상 검사를 지원하며, 다양한 만성질환 및 감염성 질환에 대한 단일 클론 항체의 치료 용도를 확대하고 있습니다.

모노클로널 항체 시장 - 주요 인사이트

리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 약 11.92%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

공급원 유형별로는 인간화 단클론 항체가 2024년 가장 높은 시장 점유율을 보였습니다.

제품 유형별로는 in vitro가 2024년 주요 제품 유형입니다.

적응증별로는 암이 2024년 주요 적응증으로 나타났습니다.

지역별로는 북미가 2024년 매출을 주도했습니다.

모노클로널 항체 시장 - 세분화 분석

세계 모노클로널 항체 시장은 공급원 유형, 제품 유형, 적응증, 최종사용자, 지역을 기준으로 세분화됩니다.

시장은 소스 유형에 따라 네 가지 범주로 나뉩니다. 즉, 마우스 모노클로널 항체, 키메라 모노클로널 항체, 인간화 모노클로널 항체, 완전 인간 모노클로널 항체입니다. 인간화 단클론 항체는 면역원성 감소와 환자 내성 개선으로 우위를 점하고 있으며, 완전 인간형 항체는 안전성 프로파일로 인해 각광받고 있습니다. 키메라 항체는 효과적인 표적화를 제공하지만 면역반응의 위험이 높고, 마우스 항체는 면역원성 우려로 인해 사용이 제한적입니다.

시장은 생산 유형에 따라 생체 내와 생체 외의 두 가지 범주로 나뉩니다. 바이오베터는 모노클로널 항체 생산에 있으며, 더 높은 제어성, 확장성, 일관성으로 시장을 선도하고 있습니다. 반면, 생체내 방법은 일반적이지 않고 대규모 생산에 더 많은 시간이 걸리고 효율적이지 않으며 주로 특정 연구 목적으로만 사용됩니다.

모노클로널 항체 시장 - 지역적 인사이트

모노클로널 항체 시장은 지역 의료 인프라, 규제 당국의 지원, 질병 유행에 따라 지역적 편차가 큰 시장입니다. 북미는 국립암연구소와 같은 정부 기관의 강력한 자금 지원과 첨단 바이오의약품 연구시설로 인해 단클론 항체 치료제의 신속한 승인과 채택을 촉진하여 여전히 선도적인 지역으로 남아있습니다. 유럽은 유럽의약품청(EMA)의 구상과 맞춤형 의료에 대한 투자 증가에 힘입어 그 뒤를 잇고 있습니다. 아시아태평양에서는 중국, 일본, 인도 등의 국가에서 만성질환 증가와 의료시스템의 개선으로 수요가 증가하고 있으며, 생물제제에 대한 접근성 강화를 위한 정부 프로그램도 추진력을 얻고 있습니다. 라틴아메리카와 중동의 신흥 시장도 의료보장 확대와 표적치료에 대한 인식이 높아지면서 완만한 성장세를 보이고 있습니다. 그러나 일부 지역에서는 여전히 가격 및 접근성 격차가 여전히 문제로 남아 있으며, 세계 시장 확대 속도에 영향을 미치고 있습니다.

모노클로널 항체 시장 - 경쟁 구도

모노클로널 항체 시장 경쟁 구도는 여러 주요 바이오 제약사들이 연구개발에 막대한 투자를 통해 제품 포트폴리오의 혁신과 확장을 꾀하고 있는 것이 특징입니다. 주요 기업은 새로운 치료법 개발을 가속화하기 위해 학계 및 정부 연구기관과 공동연구를 진행하는 경우가 많습니다. 각 업체들은 이중특이성항체, 항체-약물 접합체 등 항체 공학의 진보를 통해 차별화를 꾀하며 미충족 의료 수요에 대응하고 있습니다. FDA, EMA 등 규제 당국의 승인은 경쟁사의 포지셔닝을 좌우하는 중요한 이정표입니다. 또한 파트너십 및 라이선스 계약을 통해 보다 빠른 시장 진입과 지역적 확장이 가능합니다. 경쟁이 치열해짐에 따라 각 업체들은 치료를 보다 친숙하게 만들기 위해 제조 효율을 개선하고 제조비용을 절감하기 위해 노력하고 있습니다. 맞춤형 의료와 면역치료에 대한 강조는 계속해서 전략적 투자의 원동력이 되고 있으며, 역동적이고 진화하는 경쟁 환경을 조성하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 모노클로널 항체 산업

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- AbbVie
- Alexion Pharmaceuticals
- Amgen
- Bayer Healthcare
- Biogen
- Bristol-Myers Squibb
- Celltrion
- Eli Lilly
- Genentech(Roche subsidiary)
- GlaxoSmithKline(GSK)
- Johnson & Johnson
- Merck & Co.
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Roche
- Samsung Bioepis
- Sanofi
- Takeda Pharmaceutical
- UCB Pharma
- 기타

제13장 애널리스트의 전방위적 전망

KSA 25.08.08

REPORT HIGHLIGHT

The Monoclonal Antibody Market size was valued at US$ 250.28 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.

The Monoclonal Antibody Market refers to the sector involved in the development and commercialization of antibodies engineered to target specific antigens, primarily used in diagnostics, therapeutics, and research applications. The increasing prevalence of chronic diseases like cancer and autoimmune disorders has significantly accelerated demand, with over 70% of biologic therapies in development focusing on monoclonal antibodies. However, high production costs and complex manufacturing processes often limit accessibility, posing challenges for widespread adoption. Advances in bioengineering and personalized medicine present substantial opportunities, enabling the development of more effective and tailored treatments. Additionally, the rising number of clinical trials utilizing monoclonal antibodies, which accounted for nearly 500 ongoing studies globally last year, highlights the expanding scope of this market segment. Despite hurdles, expanding applications in oncology, immunology, and infectious diseases continue to offer promising growth avenues.

Monoclonal Antibody Market- Market Dynamics

Rising prevalence of chronic diseases and advances in bioengineering to accelerate monoclonal antibody market growth

Rising prevalence of chronic diseases such as cancer and autoimmune disorders has intensified the focus on monoclonal antibody therapies, with the World Health Organization reporting that cancer accounted for nearly 10 million deaths worldwide in recent years. Breakthroughs in bioengineering have enabled more precise targeting of disease mechanisms, improving treatment efficacy and patient outcomes. For instance, the U.S. Food and Drug Administration (FDA) approved over 20 monoclonal antibody-based drugs in the past five years alone, reflecting the growing trust in these therapies. Additionally, initiatives by institutions like the National Institutes of Health (NIH) have boosted research funding for biologics, supporting innovative clinical trials and expanding the therapeutic applications of monoclonal antibodies across various chronic and infectious diseases.

Monoclonal Antibody Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.92% over the forecast period (2025-2032)

Based on Source Type segmentation, humanized monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Production Types segmentation, in vitro was the leading Production Type in 2024

Based on Indication segmentation, Cancer leading was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Monoclonal Antibody Market- Segmentation Analysis:

The Global Monoclonal Antibody Market is segmented on the basis of Source Type, Production Types, Indication, End-User, and Region.

The market is divided into four categories based on Source Type: Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, and Fully Human Monoclonal Antibodies. Humanized monoclonal antibodies dominate due to reduced immunogenicity and improved patient tolerance, followed by fully human antibodies prized for their safety profiles. Chimeric antibodies offer effective targeting but higher immune response risk, while murine antibodies see limited use due to immunogenicity concerns.

The market is divided into two categories based on Production Types: In Vivo and In Vitro. In vitro production leads the market due to greater control, scalability, and consistency in manufacturing monoclonal antibodies, while in vivo methods are less common, primarily used for specific research purposes despite being more time-consuming and less efficient for large-scale production.

Monoclonal Antibody Market- Geographical Insights

The Monoclonal Antibody Market exhibits significant geographical variation driven by regional healthcare infrastructure, regulatory support, and disease prevalence. North America remains a prominent region due to strong funding from government agencies like the National Cancer Institute and advanced biopharmaceutical research facilities, facilitating rapid approval and adoption of monoclonal antibody therapies. Europe follows closely, supported by initiatives from the European Medicines Agency (EMA) and increasing investments in personalized medicine. In Asia-Pacific, rising incidences of chronic diseases coupled with improving healthcare systems in countries such as China, Japan, and India are fueling demand, while government programs aimed at enhancing access to biologics are gaining momentum. Emerging markets in Latin America and the Middle East are also witnessing gradual growth, driven by expanding healthcare coverage and growing awareness about targeted therapies. However, disparities in affordability and availability remain challenges in some regions, influencing the pace of market expansion globally.

Monoclonal Antibody Market- Competitive Landscape:

The competitive landscape of the Monoclonal Antibody Market is characterized by the presence of several leading biopharmaceutical companies investing heavily in research and development to innovate and expand their product portfolios. Major players often collaborate with academic institutions and government research bodies to accelerate the development of novel therapies. Companies focus on differentiating themselves through advances in antibody engineering, such as bispecific antibodies and antibody-drug conjugates, to address unmet medical needs. Regulatory approvals from authorities like the FDA and EMA are critical milestones that influence competitive positioning. Additionally, partnerships and licensing agreements enable faster market entry and geographic expansion. With increasing competition, companies are also working on improving manufacturing efficiencies and reducing production costs to make treatments more accessible. The emphasis on personalized medicine and immunotherapy continues to drive strategic investments, fostering a dynamic and evolving competitive environment.

Recent Developments:

In September 2023, KBI Biopharma has launched SureMAB(TM), a new monoclonal antibody development platform. SureMAB(TM) accelerates the discovery and production of high-quality monoclonal antibodies, offering streamlined workflows and reduced timelines for clients developing novel biologic therapeutics across various disease areas.

In April 2025, the FDA announced a phased plan to replace animal testing requirements for monoclonal antibodies and other drugs with advanced, human-relevant methods like AI modeling and organoid testing, aiming to improve safety, accelerate development, and reduce drug costs and animal use.

In March 2024, Roche Pharma India launched Vabysmo (faricimab), the world's first bispecific monoclonal antibody, for treating neovascular age-related macular degeneration and diabetic macular edema. Vabysmo uniquely targets two disease pathways, offering improved vision outcomes and extended treatment intervals for Indian patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MONOCLONAL ANTIBODY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie
Alexion Pharmaceuticals
Amgen
Bayer Healthcare
Biogen
Bristol-Myers Squibb
Celltrion
Eli Lilly
Genentech (Roche subsidiary)
GlaxoSmithKline (GSK)
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Regeneron Pharmaceuticals
Roche
Samsung Bioepis
Sanofi
Takeda Pharmaceutical
UCB Pharma
Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032

Murine Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Humanized Monoclonal Antibodies
Fully Human Monoclonal Antibodies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY PRODUCTION TYPES- MARKET ANALYSIS, 2019 - 2032

In Vivo
In Vitro

GLOBAL MONOCLONAL ANTIBODY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Cancer
Breast cancer
Colorectal cancer
Lung cancer
Ovarian cancer
Others
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Rheumatoid Arthritis
Multiple Sclerosis
Psoriasis
Crohn's Disease
Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Diagnostic Laboratories
Research Institutes
Pharmaceutical & Biotechnology Companies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Monoclonal Antibody Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Monoclonal Antibody Market Snippet by Source Type
- 2.1.2. Monoclonal Antibody Market Snippet by Production Types
- 2.1.3. Monoclonal Antibody Market Snippet by Indication
- 2.1.4. Monoclonal Antibody Market Snippet by End-User
- 2.1.5. Monoclonal Antibody Market Snippet by Country
- 2.1.6. Monoclonal Antibody Market Snippet by Region
2.2. Competitive Insights

3. Monoclonal Antibody Key Market Trends

3.1. Monoclonal Antibody Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Monoclonal Antibody Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Monoclonal Antibody Market Opportunities
3.4. Monoclonal Antibody Market Future Trends

4. Monoclonal Antibody Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Monoclonal Antibody Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Monoclonal Antibody Market Landscape

6.1. Monoclonal Antibody Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Monoclonal Antibody Market - By Source Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Source Type, 2024 & 2032 (%)
- 7.1.2. Murine Monoclonal Antibodies
- 7.1.3. Chimeric Monoclonal Antibodies
- 7.1.4. Humanized Monoclonal Antibodies
- 7.1.5. Fully Human Monoclonal Antibodies

8. Monoclonal Antibody Market - By Production Types

8.1. Overview
- 8.1.1. Segment Share Analysis, By Production Types, 2024 & 2032 (%)
- 8.1.2. In Vivo
- 8.1.3. In Vitro

9. Monoclonal Antibody Market - By Indication

9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 9.1.2. Cancer
  - 9.1.2.1. Breast cancer
  - 9.1.2.2. Colorectal cancer
  - 9.1.2.3. Lung cancer
  - 9.1.2.4. Ovarian cancer
  - 9.1.2.5. Others
- 9.1.3. Autoimmune Diseases
- 9.1.4. Inflammatory Diseases
- 9.1.5. Infectious Diseases
- 9.1.6. Rheumatoid Arthritis
- 9.1.7. Multiple Sclerosis
- 9.1.8. Psoriasis
- 9.1.9. Crohn's Disease
- 9.1.10. Others

10. Monoclonal Antibody Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Diagnostic Laboratories
- 10.1.4. Research Institutes
- 10.1.5. Pharmaceutical & Biotechnology Companies

11. Monoclonal Antibody Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Monoclonal Antibody Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Monoclonal Antibody Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Monoclonal Antibody Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Monoclonal Antibody Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Monoclonal Antibody Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Monoclonal Antibody Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AbbVie
- 12.2.2. Alexion Pharmaceuticals
- 12.2.3. Amgen
- 12.2.4. Bayer Healthcare
- 12.2.5. Biogen
- 12.2.6. Bristol-Myers Squibb
- 12.2.7. Celltrion
- 12.2.8. Eli Lilly
- 12.2.9. Genentech (Roche subsidiary)
- 12.2.10. GlaxoSmithKline (GSK)
- 12.2.11. Johnson & Johnson
- 12.2.12. Merck & Co.
- 12.2.13. Novartis
- 12.2.14. Pfizer
- 12.2.15. Regeneron Pharmaceuticals
- 12.2.16. Roche
- 12.2.17. Samsung Bioepis
- 12.2.18. Sanofi
- 12.2.19. Takeda Pharmaceutical
- 12.2.20. UCB Pharma
- 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us